ASPP2: A gene that controls life and death in vivo

Cell Cycle

Volumn 5, Issue 19, 2006, Pages 2187-2190

  Vives, Virginie ^a   Slee, Elizabeth A ^a   Lu, Xin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ASPP2; Haploinsufficient; Knockout mice; p53; Rhabdomyosarcomas; Tumor suppressor

Indexed keywords

BINDING PROTEIN; PROTEIN ASPP2; PROTEIN P53; REGULATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CELL CYCLE ARREST; DRUG TARGETING; GENE FUNCTION; GENETIC REGULATION; HUMAN; IN VIVO CULTURE; NONHUMAN; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REGULATORY MECHANISM; SHORT SURVEY;

EID: 33749610878     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.19.3266     Document Type: Short Survey

References (32)

1. Trigiante G, Lu X. ASPP [corrected] and cancer. Nat Rev Cancer 2006; 6:217-26.
2. Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S. Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci USA 1994; 91:6098-102.
3. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. ASPP1 and ASPP2: Common activators of p53 family members. Mol Cell Biol 2004; 24:1341-50.
4. Cao Y, Hamada T, Matsui T, Date T, Iwabuchi K. Hepatitis C virus core protein interacts with p53-binding protein, 53BP2/Bbp/ASPP2, and inhibits p53-mediated apoptosis. Biochem Biophys Res Commun 2004; 315:788-95.
5. Chen Y, Liu W, Naumovski L, Neve RL. ASPP2 inhibits APP-BP1-mediated NEDD8 conjugation to cullin-1 and decreases APP-BP1-induced cell proliferation and neuronal apoptosis. J Neurochem 2003; 85:801-9.
6. Espanel X, Sudol, M. Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem 2001; 276:14514-23.
7. Nakagawa H, Koyama K, Murata Y, Morito M, Akiyama T, Nakamura Y. APCL, a central nervous system-specific homologue of adenomatous polyposis coli tumor suppressor, binds to p53-binding protein 2 and translocates it to the perinucleus. Cancer Res 2000; 60:101-5.
8. Yang JP, Hori M, Takahashi N, Kawabe T, Kato H, Okamoto T. NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 1999; 18:5177-86.
9. Naumovski L, Cleary ML. The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol Cell Biol 1996; 16:3884-92.
10. Helps NR, Barker HM, Elledge SJ, Cohen PT. Protein phosphatase 1 interacts with p53BP2, a protein which binds to the tumor suppressor p53. FEBS Lett 1995; 377:295-300.
11. Samuels-Lev Y, O'Connor DJ, Bergamaschi, D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T, Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8:781-94.
12. Slee EA, O'Connor DJ, Lu X. To die or not to die: How does p53 decide? Oncogene 2004; 23:2809-18.
13. Vives, V, Su J, Zhong S, Ratnayaka I, Slee E, Goldin R, Lu X. ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev 2006; 20:1262-7.
14. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science 2001; 293:1666-70.
15. Gurley KE, Kemp CJ. Synthetic lethality between mutation in Atm and DNA-PK(cs) during murine embryogenesis. Curr Biol 2001; 11:191-4.
16. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4:1-7.
17. Purdie CA, Harrison DJ, Peter A, Dobbie L, White S, Howie SE, Salter DM, Bird CC, Wyllie AH, Hooper ML. Tumor incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 1994; 9:603-9.
18. MacPherson D, Kim J, Kim T, Rhee BK, Van Oostrom CT, DiTullio RA, Venere M, Halazonetis TD, Bronson R, De Vries A, Fleming M, Jacks T. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. Embo J 2004; 23:3689-99.
19. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992; 356:215-21.
20. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, Yang A, McKeon F, Jacks T. Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7:363-73.
21. Liu ZJ, Lu X, Zhang Y, Zhong S, Gu SZ, Zhang XB, Yang X, Xin HM. Downregulated mRNA expression of ASPP and the hypermethylation of the 5′-untranslated region in cancer cell lines retaining wild-type p53. FEBS Lett 2005; 579:1587-90.
22. Santarosa M, Ashworth A. Haploinsufficiency for tumor suppressor genes: When you don't need to go all the way. Biochim Biophys Acta 2004; 1654:105-22.
23. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA. Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. Embo J 1998; 17:4657-67.
24. Goss KH, Risinger MA, Kordich JJ, Sanz MM, Straughen JE, Slovek LE, Capobianco AJ, German J, Boivin GP, Groden J. Enhanced tumor formation in mice heterozygous for Blm mutation. Science 2002; 297:2051-3.
25. Gorina S, Pavletich NP. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 1996; 274:1001-5.
26. Ryan KM, Vousden KH. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 1998; 18:3692-8.
27. Mori T, Okamoto H, Takahashi N, Ueda R, Okamoto T. Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. FEBS Lett 2000; 465:124-8.
28. Sarraf A, Stancheva I. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol cell 2004; 15:595-605.
29. Lossos IS, Natkunam Y, Levy R, Lopez CD. Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: Correlation with clinical outcome. Leuk Lymphoma 2002; 43:2309-17.
30. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson Jr JR, Elkahloun AG. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999; 59:5656-5661.
31. Ju H, Lee KA, Yang M, Kim HJ, Kang CP, Sohn TS, Rhee JC, Kang C, Kim JW. TP53BP2 locus is associated with gastric cancer susceptibility. Int J Cancer 2005; 117:957-60.
32. Zhang X, Wang M, Zhou C, Chen S, Wang J. The expression of iASPP in acute leukemias. Leuk Res 2005; 29:179-83.